brimonidine + timolol (Allergan)

Britivin is an ophthalmic fixed-dose combination solution containing brimonidine tartrate (0.15% w/v) and timolol maleate (0.5% w/v). Developed and marketed by Zivira Labs, it is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The formulation combines two active ingredients with complementary mechanisms of action to achieve synergistic IOP lowering. Brimonidine is a relatively selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor antagonist that lowers IOP primarily by decreasing aqueous humor secretion from the ciliary body. Together, they provide superior pressure control compared to either monotherapy alone.

Brand names

Britivin

Other names

brimonidine and timololbrimonidine tartrate + timolol maleatebrimonidine tartrate and timolol maleate